GlassScriptPhysician profile
John Scott Kasteler
NPI 1487659454
$456,185.10
in general payments reported to CMS, 2019-2025
33 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $21K · 2021: $61K · 2022: $91K · 2023: $64K · 2024: $59K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Consulting Fee: $66K · Travel and Lodging: $11K · Food and Beverage: $7,644 · Education: $97.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,121.53 |
| Consulting Fee | $65,617.28 |
| Travel and Lodging | $10,601.21 |
| Food and Beverage | $7,644.06 |
| Education | $97.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $135,545.06 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $90,298.12 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $71,475.65 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $70,731.02 | 2019-2025 | |
| Amgen INC. | $32,972.21 | 2019-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $24,578.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $8,499.85 | 2019-2025 | Dupixent, Libtayo |
| Almirall LLC | $6,804.23 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $5,823.47 | 2019-2025 | Siliq, Jublia, Duobrii |
| Kowa Pharmaceuticals America, INC. | $4,284.57 | 2025 | Zoryve |
| Abbvie INC. | $1,221.37 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,139.33 | 2019-2024 | Absorica Ld, Winlevi, Ilumya |
| Merz North America, INC. | $737.52 | 2021-2025 | |
| Ucb, INC. | $592.71 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $488.02 | 2019-2025 | Tremfya, Remicade, Stelara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $261.66 | 2019-2023 | |
| Celgene Corporation | $160.99 | 2019 | |
| Dermavant Sciences, INC. | $132.93 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $64.29 | 2019-2022 | |
| Allergan, INC. | $58.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.00 | 2023-2024 | Sotyktu |
| Taro Pharmaceuticals USA, INC. | $38.56 | 2019 | |
| Incyte Corporation | $36.38 | 2021-2023 | Opzelura |
| Integra Lifesciences Corporation | $26.17 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Organon LLC | $24.99 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $24.41 | 2021 | |
| Fidia Pharma USA INC. | $22.42 | 2025 | |
| Botanix Sb INC | $21.77 | 2025 | Sofdra |
| Glaxosmithkline, LLC. | $19.38 | 2020 | |
| Encore Dermatology INC. | $17.12 | 2019 | |
| Mayne Pharma Commercial LLC | $16.95 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $11.65 | 2019 | |
| Dermira, INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kasteler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.